Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma

StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study Status, Study Design, Referencesv7
  2. Collaborator revisedv6
  3. Trial status: Recruiting to Completedv5 Show 4 more changesShow less
    • Enrollment target: 44 to 43
    • Primary completion date: Dec 2006
    • Study description expanded, about 16 words
    • Site details revised at 2 of 2 sites
  4. Study completion date: Nov 2005 to Dec 2006
    • Site details revised at 1 of 2 sites
    • Collaborator revised
    • Study title revised
    v4
  5. Site details revised at 1 of 2 sitesv3
  6. Study sites: 1 to 2
    • Collaborators expanded, about 3 words
    v2
  7. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the biological effect of Tarceva (OSI-774) from an inhibition of EGF tumor receptor tyrosine kinase activity's point of view, for patients who are carriers of head and neck epidermoid carcinoma.
Trial Details
NCT Number NCT00144976
Lead Sponsor Institut Claudius Regaud
Collaborators: Roche Pharma AG
Conditions
(from sponsor)		 Head and Neck Neoplasms
Related terms Head and Neck Neoplasms
Enrollment 43 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov